This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Ultragenyx Faces Securities Fraud Lawsuit
Business securities fraud lawsuit

Ultragenyx Faces Securities Fraud Lawsuit

Analysis based on 14 articles · First reported Feb 10, 2026 · Last updated Feb 19, 2026

Sentiment
-20
Attention
2
Articles
14
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of a securities fraud lawsuit against Ultragenyx, as it raises concerns about the company's integrity and the reliability of its drug development information. This could lead to a decrease in investor confidence in Ultragenyx and potentially other biotechnology companies.

Biotechnology Pharmaceuticals Legal Services
Event Summary

A securities fraud class action lawsuit has been filed against Ultragenyx Inc. by Kessler Topaz Meltzer & Check, LLP. The lawsuit alleges that Ultragenyx made false and/or misleading statements to investors between August 3, 2023, and December 26, 2025. Specifically, the complaint claims that Ultragenyx created a false impression of reliable information regarding its drug setrusumab's effects on Osteogenesis Imperfecta patients and minimized risks associated with its Phase III Orbit study. The lawsuit states that Ultragenyx's optimism was misplaced due to basing threshold figures on Phase II results that lacked a placebo control group. Investors have until April 6, 2026, to file for lead plaintiff status in the United States===United States District Court for the Northern District of California.

Key Actions
100 Kessler Topaz Meltzer & Check filed a securities fraud class action lawsuit Ultragenyx
90 Ultragenyx made false and/or misleading statements
Entities Involved
stock
Ultragenyx
Ultragenyx is facing a securities fraud class action lawsuit for allegedly making false and misleading statements regarding its drug setrusumab and its Phase III Orbit study. This could lead to significant financial penalties and reputational damage for the company.
Importance 100 Sentiment -70
priv
Kessler Topaz Meltzer & Check
Kessler Topaz Meltzer & Check, LLP is the law firm that filed the securities fraud class action lawsuit against Ultragenyx. The firm is actively seeking lead plaintiffs for the class action.
Importance 80 Sentiment 50
govactor
United States===United States District Court for the Northern District of California
The United States===United States District Court for the Northern District of California is the venue where the securities fraud class action lawsuit against Ultragenyx has been filed.
Importance 40 Sentiment 0
exch
Nasdaq
Nasdaq is the stock exchange where Ultragenyx's common stock is traded. The lawsuit pertains to the trading of shares on this exchange.
Importance 10 Sentiment 0
Relationships
Ultragenyx related ↔ Kessler Topaz Meltzer & Check
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.